- Breast cancer
Содержание
- 2. The most frequent cancer in women
- 4. Ashkenazi Jewish 1:40, compared with 1:500 in the general population
- 5. + prostate and pancreatic
- 8. Cowden’s syndrome Hamartomas on the skin and mucous membranes. Enlarged head, a rare noncancerous brain tumor
- 12. Irradiation for the treatment of Hodgkin lymphoma before age 30 years.
- 14. Magnitude of Risk of Known Breast Cancer Risk Factors
- 15. + PBSO
- 16. Prevention for BRCA patients Tam ↓contralater - 40-50%, ↓ Risk BC in unaffected only in BRCA
- 17. Chemoprevention with Tamoxifen + RR 50% (0.51) (47 treated - 1 BC prevented) ADH - RR
- 21. BC Receptors
- 22. BC Receptors
- 23. Biological subtypes
- 24. Staging
- 25. DS Mammography US MRI CT (chest/abdomen) Bone scan or PET CT CT/MRI head Tumor markers
- 26. Systemic therapy: Hormonal therapy Chemotherapy Targeted therapies Local therapy: Surgery Radiation therapy Treatment of breast cancer
- 27. Surgery In the patient with clinical stage I, II, and T3N1 disease, the initial management is
- 28. Axilla ALND SLNB (less lymphedema) - Majority of stage I-II BC pts - Contraindications to the
- 32. Adjuvant radiation therapy: 5 - 6.5 weeks Local control rates > 90% Minimal toxicity Adjuvant radiation
- 33. Postmastectomy RT All women with > 3 positive nodes. All women with any positive node and
- 37. For 1 year every 3 weeks
- 38. Neoadjuvant chemotherapy Indications T4 cN pos Inflamatory BC Rationale Tumor shrinkage Opportunity for BCS Early treating
- 43. Herceptin +/- Pergeta (Trastuzumab+/- Pertuzumab) & CMT Her 2 pos BC
- 44. Lapatinib Her 2 pos BC A tyrosine kinase inhibitor A potent and selective oral dual inhibitor
- 45. Trastuzumab emtansine (TDM1= KADCYLA) Her 2 pos BC Trastuzumab emtansine
- 46. Inflammatory BC T4 1% to 5% of all cases Aggressive Neoadjuvant CMT +/- RT Surgery is
- 47. Paget disease 1 to 4.3% of all breast cancers Ca in situ in the nipple epidermis.
- 49. Скачать презентацию
The most frequent cancer in women
The most frequent cancer in women
Ashkenazi Jewish 1:40, compared with 1:500 in the general population
Ashkenazi Jewish 1:40, compared with 1:500 in the general population
+ prostate and pancreatic
+ prostate and pancreatic
Cowden’s syndrome
Hamartomas on the skin and mucous membranes.
Enlarged head, a rare
Cowden’s syndrome
Hamartomas on the skin and mucous membranes.
Enlarged head, a rare
Irradiation for the treatment of Hodgkin lymphoma before age 30 years.
Irradiation for the treatment of Hodgkin lymphoma before age 30 years.
Magnitude of Risk of Known Breast Cancer Risk Factors
Magnitude of Risk of Known Breast Cancer Risk Factors
+ PBSO
+ PBSO
Prevention for BRCA patients
Tam ↓contralater - 40-50%,
↓ Risk
Prevention for BRCA patients
Tam ↓contralater - 40-50%,
↓ Risk
Chemoprevention with Tamoxifen
+
RR 50% (0.51) (47 treated - 1 BC prevented)
ADH
Chemoprevention with Tamoxifen
+
RR 50% (0.51) (47 treated - 1 BC prevented)
ADH
BC Receptors
BC Receptors
BC Receptors
BC Receptors
Biological subtypes
Biological subtypes
Staging
Staging
DS
Mammography
US
MRI
CT (chest/abdomen)
Bone scan or PET CT
CT/MRI head
Tumor markers
DS
Mammography
US
MRI
CT (chest/abdomen)
Bone scan or PET CT
CT/MRI head
Tumor markers
Systemic therapy:
Hormonal therapy
Chemotherapy
Targeted therapies
Local therapy:
Surgery
Radiation therapy
Treatment of breast cancer
Systemic therapy:
Hormonal therapy
Chemotherapy
Targeted therapies
Local therapy:
Surgery
Radiation therapy
Treatment of breast cancer
Surgery
In the patient with clinical stage I, II, and T3N1 disease,
Surgery
In the patient with clinical stage I, II, and T3N1 disease,
Axilla
ALND
SLNB (less lymphedema)
- Majority of stage I-II BC pts
-
Axilla
ALND
SLNB (less lymphedema)
- Majority of stage I-II BC pts
-
Adjuvant radiation therapy:
5 - 6.5 weeks
Local control rates > 90%
Minimal toxicity
Adjuvant
Adjuvant radiation therapy:
5 - 6.5 weeks
Local control rates > 90%
Minimal toxicity
Adjuvant
Postmastectomy RT
All women with > 3 positive nodes.
All women with any
Postmastectomy RT
All women with > 3 positive nodes.
All women with any
For 1 year every 3 weeks
For 1 year every 3 weeks
Neoadjuvant chemotherapy
Indications
T4
cN pos
Inflamatory BC
Rationale
Tumor shrinkage
Opportunity for BCS
Early treating of micrometastasis
Aggressive biological
Neoadjuvant chemotherapy
Indications
T4
cN pos
Inflamatory BC
Rationale
Tumor shrinkage
Opportunity for BCS
Early treating of micrometastasis
Aggressive biological
Herceptin +/- Pergeta
(Trastuzumab+/- Pertuzumab) & CMT
Her 2 pos BC
Herceptin +/- Pergeta
(Trastuzumab+/- Pertuzumab) & CMT
Her 2 pos BC
Lapatinib
Her 2 pos BC
A tyrosine kinase inhibitor
A potent and selective
Lapatinib
Her 2 pos BC
A tyrosine kinase inhibitor
A potent and selective
Trastuzumab emtansine
(TDM1= KADCYLA)
Her 2 pos BC
Trastuzumab emtansine
Trastuzumab emtansine
(TDM1= KADCYLA)
Her 2 pos BC
Trastuzumab emtansine
Inflammatory BC
T4
1% to 5% of all cases
Aggressive
Neoadjuvant CMT +/- RT
Surgery is
Inflammatory BC
T4
1% to 5% of all cases
Aggressive
Neoadjuvant CMT +/- RT
Surgery is
Paget disease
1 to 4.3% of all breast cancers
Ca in situ in
Paget disease
1 to 4.3% of all breast cancers
Ca in situ in
Грибковые заболевания кожи
Gangrene
Позитивные и негативные последствия иммунной реакции
Психология как наука
Аллергия. Факторы риска развития аллергии
Спаечная болезнь
Сосудистая система
Профилактика употребления никотинсодержащей продукции среди несовершеннолетних
Вирусные гепатиты
Профилактика сердечно - сосудистых заболеваний
Особенности ЛФК (лечебная физкультура)
Ферматрон в комплексном лечении остеоартроза коленных суставов
Әртүрлі антигеңдерге қарсы бағытгалған иммуңдық реакция-лар
Лечебная физкультура (ЛФК)
Семья. Причины конфликтов и способы коммуницирования
Віруси. Будова і класифікация
За доступную и качественную медицину в первичном звене
Миокардит. Клинические признаки
Альвеолярный протеиноз. Этиология. Патогенез. Классификация. Клинико-диагностические и дифференциально-диагностические критерии
Конфликт. Классификация конфликтов
Результаты сравнительного постмаркетингового исследования комбинированных антиретровирусных препаратов
Акушериядағы аурусыздандыру. Акушерлік операциялардағы аурусыздандыру
Естественная резистентность
Создание композитной накладки своими руками
Эндокринология. Ожирение. (Лекция 9)
презентація Лекції № 1 для студентів 5 к МФ укр
Очаговая деминерализация эмали зуба
Клетки крови. Строение и функции